Janssen Research & Development, Llc

This large, completed Phase 3 study tested whether a new 9-valent vaccine (ExPEC9V) could prevent serious, invasive E. coli infections in adults aged 60 and older who had a urinary tract infection in the past two years. Over 17,900 participants received either the vaccine or a pl…

This study tested an experimental drug, JNJ-77242113, in 255 adults with moderate-to-severe plaque psoriasis. The goal was to see if different doses could improve skin symptoms, like redness and scaling, after 16 weeks of treatment. Participants were randomly assigned to receive …

This study tested whether combining two drugs, guselkumab and golimumab, works better than guselkumab alone for people with active psoriatic arthritis who didn't improve with previous treatments. 91 adults participated in this phase 2a trial. The goal was to see if the combinatio…

This study tested the drug guselkumab in 213 adults with skin of color who have moderate-to-severe plaque or scalp psoriasis. Participants received either the drug or a placebo, and researchers measured how much their psoriasis cleared up after 16 weeks. The goal was to see if gu…

This study tested a drug called erdafitinib in people with a specific type of bladder cancer that came back after standard BCG therapy. The drug targets certain genetic changes (FGFR mutations) found in the tumor. Researchers compared erdafitinib to standard chemotherapy given di…

This early-phase study tested a new treatment called JNJ-75229414 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, modified to target a protein on cancer cells. The main goals were to fi…

This early-stage study tested an experimental drug called JNJ-75348780 in 147 people with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goal wa…

This study tested an experimental drug called M281 (nipocalimab) in 25 pregnant women whose babies were at high risk for a severe blood disorder that can cause anemia and death. The goal was to see if the drug could help more babies survive to at least 32 weeks without needing a …

This study tested a drug called golimumab, given through a vein (IV), in 208 adults with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. The goal was to see if it could reduce pain and improve movement better than a placebo. Golimumab works…

This study tested a drug called golimumab in 130 children with active juvenile idiopathic arthritis (JIA) that was not controlled by methotrexate alone. The drug was given through a vein (IV) to see how it moves through the body and if it helps control joint inflammation. The goa…

This study tested whether adding daratumumab to standard chemotherapy (CyBorD) helps people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up in organs. Over 400 adults took part. The goal was to see if the combination leads to better blood resp…

This study tested a new drug, nipocalimab, against a placebo in 228 adults with active systemic lupus erythematosus (SLE). The goal was to see if nipocalimab could reduce lupus disease activity without worsening symptoms. Participants received either the drug or a placebo, and re…

This study tested whether adding daratumumab to the standard drugs lenalidomide and dexamethasone helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The trial included 737 adults who were not healthy enough for high-dose chemotherap…

This study tested a new daily pill called milvexian in over 14,000 people who recently had a heart attack or unstable angina. The goal was to see if adding this blood thinner to standard care could lower the chance of another heart attack, stroke, or heart-related death. Particip…

This study tested an experimental oral tablet, JNJ-77242113, in 90 adults with moderate-to-severe plaque psoriasis. Participants took the tablet or a placebo for 16 weeks. The main goal was to see if the drug could reduce psoriasis severity by at least 75% compared to placebo. Th…

This study followed 42 people who received a gene therapy for X-linked retinitis pigmentosa, an inherited eye disease that causes vision loss. The main goal was to check the treatment's safety over up to 5 years. Researchers also looked at whether the therapy helped with daily vi…

This study tested an experimental drug called JNJ-77242113 in 227 adults with moderate-to-severe plaque psoriasis. The goal was to see how well the drug worked over the long term. After 36 weeks, many participants had significant skin clearing, as measured by standard psoriasis s…

This study tested a new drug, daratumumab, added to two standard medicines (lenalidomide and dexamethasone) in 45 people whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and see how many patients had their cancer shrink or disap…

This early-stage study tested a new drug, JNJ-70218902, that helps the body's immune T cells attack cancer. It involved 82 people with advanced solid tumors, including prostate cancer that had spread. The main goals were to find the safest dose and check for side effects.

This study tested whether adding a new drug (nipocalimab) to an existing one (certolizumab) works better than certolizumab alone for people with active rheumatoid arthritis. About 103 adults who had not improved with prior advanced treatments took part. The goal was to see if the…

This study tested the drug ustekinumab (STELARA) in 182 Chinese adults with moderate to severe Crohn's disease, a condition causing inflammation in the digestive tract. The goal was to see if the drug could reduce symptoms and heal gut damage over 52 weeks. Participants received …

This study tested a gene therapy called JNJ-81201887 in 305 people with geographic atrophy, a severe form of dry age-related macular degeneration that causes blind spots. The treatment was injected into the eye and compared to a sham procedure. The goal was to see if it could slo…

This study tested whether an experimental drug called nipocalimab could reduce disease activity and symptoms in adults with primary Sjogren's syndrome, an autoimmune condition that causes severe dryness, fatigue, and pain. Researchers compared nipocalimab against a placebo in 163…

This study tested a new vaccine called ExPEC10V in 836 adults aged 60 to 85. The goal was to see if it is safe and helps the body fight off a type of E. coli that can cause serious infections, especially in the urinary tract. Researchers gave different doses to find the best one …

This study tested a drug called guselkumab against a placebo in 338 adults with moderate plaque psoriasis that also affects special areas like the scalp or genitals. The goal was to see if the drug could clear or nearly clear the skin. Results showed that guselkumab was more effe…

This study tested whether adding seltorexant, a sleep aid, to standard antidepressants helps adults with major depression who still have insomnia and depressive symptoms. About 588 participants took either seltorexant or a placebo for 6 weeks, then some continued on seltorexant l…

This study tested whether adding aticaprant to a standard antidepressant helps adults with major depression who still feel little interest or pleasure (anhedonia). About 444 people took either aticaprant or a placebo pill for 6 weeks. Researchers measured changes in depression an…

This early-stage study tested how long-acting versions of two HIV drugs, rilpivirine and cabotegravir, behave when given as shots under the skin. 126 healthy adults received one or both drugs to measure drug levels and check for side effects. The goal was to gather safety and dos…

This study looked at 545 adults with major depression who also had a loss of interest or pleasure (anhedonia) and whose current antidepressants weren't working well enough. Researchers tracked their personal and medical details, as well as the real-life treatments they received, …

This study followed 17 pregnant women and their babies who were at high risk for a severe blood condition called hemolytic disease of the newborn. The goal was to learn more about how the disease progresses and what standard treatments are used. No new treatments were tested; ins…